Free weekly newsletter

Get the free weekly executive digest

The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New leadership moves, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Leadership Trends

See who's moving and how much in your market

No credit card required Weekly executive digest

Jade Biosciences Names Andrew King As Chief Scientific Officer

PUBLIC · JBIOAug 01, 2024•almost 2 years ago

Position

Head of Research and Development

Company

Jade Biosciences

Andrew King

San FranciscoInformation TechnologyBiotechnologyHealthcareHealth CareTherapeutics

Description

Jade Biosciences, Inc. announced the closing of an $80 million financing led by Fairmount and Venrock Healthcare Capital Partners. The company appointed Andrew King, D.V.M., Ph.D., with over 15 years of leadership experience, as the Chief Scientific Officer.

Company Information

Company

Jade Biosciences

Location

San Francisco, California, United States

About

Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE-003, an undisclosed antibody discovery program, both currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Jade Biosciences's next move

Learn about Strategic plan

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months